Tumor markers in clinical practice: A review focusing on common solid cancers

Medical Principles and Practice

Volumn 22, Issue 1, 2012, Pages 4-11

  Duffy, Michael J ^a  

^a ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

Author keywords

Fetoprotein; Biomarkers; CA 125; CA 15 3; Carcinoembryonic antigen; Human chorionic gonadotrophin; Prostate specific antigen; Tumor markers

Indexed keywords

ALPHA FETOPROTEIN; AROMATASE INHIBITOR; CA 125 ANTIGEN; CA 15-3 ANTIGEN; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CETUXIMAB; CHORIONIC GONADOTROPIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; ESTROGEN RECEPTOR; GEFITINIB; LACTATE DEHYDROGENASE; LAPATINIB; PANITUMUMAB; PEPSINOGEN; PROGESTERONE RECEPTOR; PROSTATE SPECIFIC ANTIGEN; PROTEIN S 100; TAMOXIFEN; THYROGLOBULIN; TRASTUZUMAB; TUMOR MARKER;

BREAST CANCER; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER PROGNOSIS; CANCER SCREENING; CANCER THERAPY; CLINICAL PRACTICE; COLORECTAL CANCER; DIAGNOSTIC KIT; EARLY CANCER; GERM CELL TUMOR; HORMONAL THERAPY; HUMAN; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; MICROSATELLITE INSTABILITY; OCCULT BLOOD TEST; OVARY CANCER; PATIENT IDENTIFICATION; PATIENT MONITORING; PATIENT SELECTION; PREDICTIVE VALUE; PROSTATE CANCER; REVIEW; SOLID TUMOR; TREATMENT RESPONSE;

ALPHA-FETOPROTEINS; CA-125 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CHORIONIC GONADOTROPIN; EARLY DETECTION OF CANCER; ENVIRONMENTAL MONITORING; HUMANS; MUCIN-1; NEOPLASMS; OCCULT BLOOD; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; TUMOR MARKERS, BIOLOGICAL;

EID: 84871722734     PISSN: 10117571     EISSN: 14230151     Source Type: Journal    
DOI: 10.1159/000338393     Document Type: Review

References (39)

1. Duffy MJ: Clinical uses of tumor markers: A critical review. Crit Rev Clin Lab Sci 2001; 38: 225-262. (Pubitemid 32614076)
2. Duffy MJ: Role of tumor markers in patients with solid tumors: A critical review. Eur J Int Med 2007; 18: 175-184. (Pubitemid 46628757)
3. Duffy MJ: Use of biomarkers in screening for cancer. EJIFCC 2010; 21, No 1.
4. Hewitson P, Glasziou P, Irwig L Towler B, Watson E: Screening for colorectal cancer using fecal the occult blood test, Hemoccult. Cochrane Database of Syst Rev 2007; 1: CD001216.
5. Duffy MJ, van Rossum LG, van Turenhout ST, Malminiemi O, Sturgeon C, Lamerz R, Nicolini A, Haglund C, Holubec L, Fraser CG, Halloran SP: Use of faecal markers in screening for colorectal neoplasia: A European group on tumor markers position paper. Int J Cancer 2011; 128: 3-11.
6. Segnan N, Patnik J, von Karsa L (eds): European Guidelines for Quality Assurance in Colorectal Cancer Screening and Diagnosis. Luxembourg, Publication Office of the European Union, 2010.
7. Duffy M: Prostate-specific antigen: Does the current evidence support its use in prostate cancer screening? Ann Clin Biochem 2011; 22: 2234-2240.
8. Andriole GL, Crawford ED, Grubb RL 3rd, Buys SS, Chia D, Church TR, Fouad MN, Gelmann EP, Kvale PA, Reding DJ, et al: Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009; 360: 1310-1319.
9. Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, Zappa M, et al: Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009; 360: 1320-1328.
10. Sturgeon CM, Duffy MJ, Stenman UH, Lilja H, Brünner N, Chan DW, Babaian R, Bast RC Jr, Dowell B, Esteva FJ, National Academy of Clinical Biochemistry, et al: National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast and ovarian cancers. Clin Chem 2008; 54:e11-e79. (Pubitemid 352777353)
11. Buys SS, Partridge E, Greene MH, Prorok PC, Reding D, Riley TL, Hartge P, Fagerstrom RM, Ragard LR, Chia D, et al: Ovarian cancer screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial. Am J Obstet Gynecol 2005; 193: 1630-1639.
12. Menon U, Gentry-Maharaj A, Hallett R, Ryan A, Burnell M, Sharma A, Lewis S, Davies S, Philpott S, Lopes A, et al: Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: Results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol 2009; 10: 327-340.
13. Buys SS, Partridge E, Black A, Johnson CC, Lamerato L, Isaacs C, Reding DJ, Greenlee RT, Yokochi LA, Kessel B, PLCO Project Team, et al: Effect of screening on ovarian cancer mortality: The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA 2011; 305: 2295-2303.
14. Duffy MJ, Bonfrer JM, Kulpa J, Rustin GJ, Soletormos G, Torre GC, Tuxen MK, Zwirner M: CA125 in ovarian cancer: European Group on Tumor Markers (EGTM) guidelines for clinical use. Int J Gynecol Cancer 2005; 15: 679-691. (Pubitemid 41783071)
15. Sturgeon CM, Duffy MJ, Hofmann BR, Lamerz R, Fritsche HA, Gaarenstroom K, Bonfrer J, Ecke TH, Grossman HB, Hayes P, National Academy of Clinical Biochemistry, et al: National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in liver, bladder, cervical, and gastric cancers. Clin Chem 2010; 56:e1-e48.
16. Earle CC, Schrag D, Neville BA, Yabroff KR, Topor M, Fahey A, Trimble EL, Bodurka DC, Bristow RE, Carney M, Warren JL: Effect of surgeon specialty on processes of care and outcomes for ovarian cancer patients. J Natl Cancer Inst 2006; 98: 172-180. (Pubitemid 43205479)
17. Bruix J, Sherman M: Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208-1236. (Pubitemid 43112690)
18. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T, et al: A multi-gene assay to predict recurrence of tamoxifen-treated node-negative breast cancer. N Engl J Med 2004; 351: 2817-2826. (Pubitemid 40051905)
19. Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, Somerfield MR, Hayes DF, Bast RC Jr, American Society of Clinical Oncology: American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007; 25: 5287-5312. (Pubitemid 350232263)
20. Molina R, Barak V, van Dalen A, Duffy MJ, Einarsson R, Gion M, Goike H, Lamerz R, Nap M, Sölétormos G, Stieber P: Tumor markers in breast cancer Y European Group on Tumor Markers recommendations. Tumour Biol 2005; 26: 281-293. (Pubitemid 41619458)
21. Duffy MJ: Urokinase plasminogen activator and its inhibitor, PAI-1, as prognostic markers in breast cancer: From pilot to level 1 evidence. Clin Chem 2002; 48: 1194-1197. (Pubitemid 34809824)
22. Janicke F, Prechtl A, Thomssen C, Harbeck N, Meisner C, Untch M, Sweep CG, Selbmann HK, Graeff H, Schmitt M, German N0 Study Group: Randomized adjuvant chemotherapy trial in high-risk node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1. J Natl Cancer Instit 2001; 93: 913-920. (Pubitemid 32624648)
23. Look MP, van Putten WL, Duffy MJ, Harbeck N, Christensen IJ, Thomssen C, Kates R, Spyratos F, Fernö M, Eppenberger-Castori S, et al: Pooled analysis of prognostic impact of tumor biological factors uPA and PAI-1 in 8,377 breast cancer patients. J Natl Cancer Instit 2002; 94: 116-128. (Pubitemid 34121291)
24. Duffy MJ: Predictive markers in breast and other cancers: A review. Clin Chem 2005; 51: 494-503. (Pubitemid 40300223)
25. Fojo T, Parkinson DR: Biologically targeted cancer therapy and marginal benefits: Are we making too much of too little or are we achieving too little by giving too much? Clin Cancer Res 2010; 16: 5972-5980.
26. Huang RS, Ratain MJ: Pharmacogenetics and pharmacogenomics of anticancer agents. CA Cancer J Clin 2009; 59: 42-55.
27. Duffy MJ, O'Donovan N, Crown J: Use of molecular markers for predicting therapy response in cancer patients. Cancer Treat Rev 2011; 37: 151-159.
28. Renehan AG, Egger M, Saunders MP, O'Dwyer ST: Impact on survival of intensive follow-up after curative resection for colorectal cancer: Systematic review and meta-analysis of randomised trials. BMJ 2002; 324: 813-820.
29. Figueredo A, Rumble RB, Maroun J, Earle CC, Cummings B, McLeod R, Zuraw L, Zwaal C, Gastrointestinal Cancer Disease Site Group of Cancer Care Ontario's Program in Evidence-based Care: Follow-up of patients with curatively resected colorectal cancer: A practice guideline. BMC Cancer 2003; 3: 26-38.
30. Duffy MJ, van Dalen A, Haglund C, Hansson L, Klapdor R, Lamerz R, Nilsson O, Sturgeon C, Topolcan O: Clinical utility of biochemical markers in colorectal can -cer: European Group on Tumour Markers (EGTM) guidelines. Eur J Cancer 2003; 39: 718-727. (Pubitemid 36315986)
31. Duffy MJ, van Dalen A, Haglund C, Hansson L, Holinski-Feder E, Klapdor R, Lamerz R, Peltomaki P, Sturgeon C, Topolcan O: Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use. Eur J Cancer 2007; 43: 1348-1360. (Pubitemid 46874070)
32. Locker GY, Hamilton S, Harris J, Jessup JM, Kemeny N, Macdonald JS, Somerfield MR, Hayes DF, Bast RC Jr, ASCO: ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 2006; 24: 5313-5327. (Pubitemid 46631379)
33. Gilligan TD, Seidenfeld J, Basch EM, Einhorn LH, Fancher T, Smith DC, Stephenson AJ, Vaughn DJ, Cosby R, Hayes DF, American Society of Clinical Oncology: American Society of Clinical Oncology Clinical Practice Guideline on uses of serum tumor markers in adult males with germ cell tumors. J Clin Oncol 2010; 28: 3388-3404.
34. Tuxen MK, Soletormos G, Dombernowsky P: Serum tumour marker CA 125 in monitoring of ovarian cancer during first-line chemotherapy. Br J Cancer 2001; 84: 1301-1307. (Pubitemid 32522095)
35. Rustin GJ, van der Burg ME, Griffin CL, Guthrie D, Lamont A, Jayson GC, Kristensen G, Mediola C, Coens C, Qian W, et al, MRC OV05; EORTC 55955 investigator: Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): A randomised trial. Lancet 2010; 376: 1155-1163.
36. Hernandez J, Thompson IM: Prostate-specific antigen: A review of the validation of the most commonly used cancer biomarker. Cancer 2004; 101: 894-904. (Pubitemid 39100420)
37. Cookson MS, Aus G, Burnett AL, Canby-Hagino ED, D'Amico AV, Dmochowski RR, Eton DT, Forman JD, Goldenberg SL, Hernandez J, et al: Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: The American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes. J Urol 2007; 177: 540-545. (Pubitemid 46054056)
38. Horwitz EM, Thames HD, Kuban DA, Levy LB, Kupelian PA, Martinez AA, Michalski JM, Pisansky TM, Sandler HM, Shipley WU, et al: Definitions of biochemical failure that best predict clinical failure in patients with prostate cancer treated with external beam radiation alone: A multi-institutional pooled analysis. J Urol 2005; 173: 797-802. (Pubitemid 40239344)
39. Duffy MJ, Evoy D, McDermott EW: CA 15-3: Uses and limitation as a biomarker for breast cancer. Clin Chim Acta 2010; 411: 1869-1874.